T B Campbell

Summary

Affiliation: University of Colorado Health Sciences Center
Country: USA

Publications

  1. pmc The effect of structure in a long target RNA on ribozyme cleavage efficiency
    T B Campbell
    Department of Medicine, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Nucleic Acids Res 25:4985-93. 1997
  2. ncbi request reprint Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection
    Thomas B Campbell
    Division of Infectious Diseases, Department of Medicine, University of Colorado Health Sciences Center, Denver 80262, USA
    Clin Infect Dis 41:236-42. 2005
  3. ncbi request reprint Persistence of Kaposi sarcoma-associated herpesvirus (KSHV)-infected cells in KSHV/HIV-1-coinfected subjects without KSHV-associated diseases
    Thomas B Campbell
    Division of Infectious Diseases, Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Infect Dis 191:367-71. 2005
  4. ncbi request reprint Increased replication of HIV-1 minor variants during hematopoietic stem-cell mobilization with filgrastim
    Thomas B Campbell
    Division of Infectious Diseases, Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado, USA
    J Infect Dis 190:257-66. 2004
  5. ncbi request reprint Changes in human immunodeficiency virus type 1 virus load during mobilization and harvesting of hemopoietic progenitor cells. Adult AIDS Clinical Trials Group 285 Study Team
    T B Campbell
    University of Colorado Health Sciences Center and Bonfils Blood Center, Denver, CO 80262, USA
    Blood 95:48-55. 2000
  6. ncbi request reprint Reduced mobilization of CD34+ stem cells in advanced human immunodeficiency virus type 1 disease
    R T Schooley
    University of Colorado Health Sciences Center, Division of Infectious Diseases, Denver, CO 80262, USA
    J Infect Dis 181:148-57. 2000
  7. ncbi request reprint Relationship between human immunodeficiency virus type 1 (HIV-1)-specific memory cytotoxic T lymphocytes and virus load after recent HIV-1 seroconversion
    E Connick
    Department of Medicine, Division of Infectious Disease, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Infect Dis 184:1465-9. 2001
  8. ncbi request reprint Primary pulmonary hypertension, Castleman's disease and human herpesvirus-8
    T M Bull
    Dept of Medicine, Division of Pulmonary and Critical Care Medicine, Pulmonary Hypertension Center, Denver, CO 80262, USA
    Eur Respir J 22:403-7. 2003
  9. pmc Maraviroc for previously treated patients with R5 HIV-1 infection
    Roy M Gulick
    Weill Cornell Medical College, New York, NY 10065, USA
    N Engl J Med 359:1429-41. 2008
  10. ncbi request reprint Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118)
    Barbara M Gripshover
    University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH, USA
    Antivir Ther 11:619-23. 2006

Research Grants

  1. INHIBITION OF HHV 8 GENE EXPRESSION BY RIBOZYMES
    Thomas Campbell; Fiscal Year: 2001
  2. Significance of Oral KS in an African Setting
    Thomas Campbell; Fiscal Year: 2006
  3. COLORADO AIDS CLINICAL TRIALS UNIT
    Thomas Campbell; Fiscal Year: 2007
  4. Colorado HIV Research Training Program
    Thomas Campbell; Fiscal Year: 2007

Detail Information

Publications24

  1. pmc The effect of structure in a long target RNA on ribozyme cleavage efficiency
    T B Campbell
    Department of Medicine, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Nucleic Acids Res 25:4985-93. 1997
    ..Chemical modification mapping of cleavage site structure may therefore provide a means to identify efficient hammerhead ribozyme cleavage sites in long target RNAs...
  2. ncbi request reprint Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection
    Thomas B Campbell
    Division of Infectious Diseases, Department of Medicine, University of Colorado Health Sciences Center, Denver 80262, USA
    Clin Infect Dis 41:236-42. 2005
    ..Available data suggest that lamivudine contributes to partial viral suppression, despite the presence of M184V mutations and high-level phenotypic lamivudine resistance...
  3. ncbi request reprint Persistence of Kaposi sarcoma-associated herpesvirus (KSHV)-infected cells in KSHV/HIV-1-coinfected subjects without KSHV-associated diseases
    Thomas B Campbell
    Division of Infectious Diseases, Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Infect Dis 191:367-71. 2005
    ..These findings provide evidence that, in the absence of KSHV-associated diseases, latent infection of lymph node cells provides a mechanism for the persistence of KSHV in KSHV/HIV-1-coinfected persons...
  4. ncbi request reprint Increased replication of HIV-1 minor variants during hematopoietic stem-cell mobilization with filgrastim
    Thomas B Campbell
    Division of Infectious Diseases, Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado, USA
    J Infect Dis 190:257-66. 2004
    ..These findings provide evidence that increased HIV-1 replication during filgrastim treatment was associated with activation of HIV-1 variants that, before filgrastim treatment, were minor components of the plasma quasi species...
  5. ncbi request reprint Changes in human immunodeficiency virus type 1 virus load during mobilization and harvesting of hemopoietic progenitor cells. Adult AIDS Clinical Trials Group 285 Study Team
    T B Campbell
    University of Colorado Health Sciences Center and Bonfils Blood Center, Denver, CO 80262, USA
    Blood 95:48-55. 2000
    ..Thus, mobilization and harvesting of bone marrow progenitor cells from persons infected with HIV-1 induced a transient increase in viral replication in some patients but was not associated with adverse effects. (Blood. 2000;95: 48-55)..
  6. ncbi request reprint Reduced mobilization of CD34+ stem cells in advanced human immunodeficiency virus type 1 disease
    R T Schooley
    University of Colorado Health Sciences Center, Division of Infectious Diseases, Denver, CO 80262, USA
    J Infect Dis 181:148-57. 2000
    ..CD34+ cell viability and the ability to differentiate precursor cells into myeloid and erythroid progenitor cells were not affected by HIV-1 infection...
  7. ncbi request reprint Relationship between human immunodeficiency virus type 1 (HIV-1)-specific memory cytotoxic T lymphocytes and virus load after recent HIV-1 seroconversion
    E Connick
    Department of Medicine, Division of Infectious Disease, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Infect Dis 184:1465-9. 2001
    ..0220) and highest Gag precursor CTL frequencies (P=.0128). These data suggest that host factors that restrict viral replication may be important determinants of the level of HIV-1-specific precursor CTL...
  8. ncbi request reprint Primary pulmonary hypertension, Castleman's disease and human herpesvirus-8
    T M Bull
    Dept of Medicine, Division of Pulmonary and Critical Care Medicine, Pulmonary Hypertension Center, Denver, CO 80262, USA
    Eur Respir J 22:403-7. 2003
    ..Evidence of human herpesvirus-8 infection was found in the lung tissue and, specifically, in the plexiform lesions from one of the patients...
  9. pmc Maraviroc for previously treated patients with R5 HIV-1 infection
    Roy M Gulick
    Weill Cornell Medical College, New York, NY 10065, USA
    N Engl J Med 359:1429-41. 2008
    ..CC chemokine receptor 5 antagonists are a new class of antiretroviral agents...
  10. ncbi request reprint Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118)
    Barbara M Gripshover
    University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH, USA
    Antivir Ther 11:619-23. 2006
    ..Amdoxovir (2,6-diaminopurine dioxolane; DAPD) is a nucleoside reverse transcriptase inhibitor (NRTI) of human immunodeficiency virus-1 (HIV-1) with activity against wild-type and NRTI-resistant viruses...
  11. ncbi request reprint Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity
    Jason D Barbour
    Positive Health Program, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, California, USA
    AIDS 20:2123-5. 2006
    ..Viral polRC was measured before starting ART in all subjects. We examined 243 individuals for a median 260 days after initiating ART. Low baseline polRC was associated with greater CD4 T-cell gains independent of virological responses...
  12. ncbi request reprint CD4+ T cell targeting of human immunodeficiency virus type 1 (HIV-1) peptide sequences present in vivo during chronic, progressive HIV-1 disease
    Eli Boritz
    Department of Immunology, University of Colorado Health Sciences Center, Denver, CO, USA
    Virology 361:34-44. 2007
    ..However, with high-level in vivo HIV-1 replication, CD4+ T cells targeting autologous HIV-1 may be non-responsive or absent...
  13. ncbi request reprint Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations
    Roger Paredes
    Section of Retroviral Therapeutics, Brigham and Women s Hospital and Division of AIDS, Harvard Medical School, Boston, MA, USA
    J Virol Methods 146:136-46. 2007
    ..In addition, ASPCR can be used to assess the dynamics of mutant populations in the viral quasispecies in response to changing selection pressures, allowing inferences on viral fitness in vivo through mathematical modeling...
  14. pmc Genetic diversity of the Kaposi's sarcoma herpesvirus K1 protein in AIDS-KS in Zimbabwe
    Tiffany White
    Division of Infectious Diseases, Department of Medicine, University of Colorado at Denver and Health Sciences Center, Denver, CO 80262, USA
    J Clin Virol 42:165-71. 2008
    ..Little is known about K1 genetic diversity in Zimbabwe where acquired immunodeficiency syndrome-associated KS (AIDS-KS) is epidemic...
  15. ncbi request reprint Are all HIV type 1 strains created equal?
    Thomas B Campbell
    Clin Infect Dis 42:853-4. 2006
  16. ncbi request reprint HIV-1-specific CD4+ T-cell responses are not associated with significant viral epitope variation in persons with persistent plasma viremia
    John R Koeppe
    Division of Infectious Diseases and Clinical Immunology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    J Acquir Immune Defic Syndr 41:140-8. 2006
    ..To determine whether increased sequence variation occurs in regions of endogenous HIV-1 targeted by HIV-1-specific CD4 T cells. The presence of increased variation would be suggestive of immune evasion by HIV-1...
  17. ncbi request reprint Antiretroviral rounds. Resistance: how do you know if you don't know?
    Thomas B Campbell
    AIDS Clin Care 17:26-7. 2005
  18. ncbi request reprint Challenges in the study of patients with HIV type 1 seroconversion
    Elizabeth Connick
    Clin Infect Dis 40:1355-7. 2005
  19. ncbi request reprint Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma during potent antiretroviral therapy
    Elizabeth Connick
    Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver 80262, USA
    Clin Infect Dis 39:1852-5. 2004
    ..Inflammation resolved coincident with decreases in the CD4(+) lymphocyte count during paclitaxel treatment, whereas KS cleared only after prolonged antiretroviral therapy and chemotherapy...
  20. ncbi request reprint Stimulation of Kaposi's sarcoma-associated herpesvirus viremia during hematopoietic stem cell mobilization with filgrastim
    James M Neid
    Division of Infectious Diseases, Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Am J Hematol 77:410-2. 2004
    ..These findings suggest that, although CD34+ cell preparations do not have evidence of KSHV infection, HSC mobilization may stimulate KSHV replication in other cellular compartments that contribute to KSHV viremia...
  21. pmc Relationship between in vitro human immunodeficiency virus type 1 replication rate and virus load in plasma
    Thomas B Campbell
    Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Virol 77:12105-12. 2003
    ..44; P = 0.019). These data suggest that different RT-PR alleles are important determinants of HIV-1 replication rates and that HIV-1 replication rate explains much of the variability in plasma virus load in chronic HIV-1 infection...
  22. ncbi request reprint Relationship of Kaposi sarcoma (KS)-associated herpesvirus viremia and KS disease in Zimbabwe
    Thomas B Campbell
    Division of Infectious Diseases, Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Clin Infect Dis 36:1144-51. 2003
    ..These findings provide evidence that KSHV viremia is common in advanced AIDS-KS in Zimbabwe and suggest a relationship between KSHV lytic replication and untreated HIV-1 infection...
  23. doi request reprint Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection
    Gerd Fatkenheuer
    Universitätsklinik Köln, Cologne, Germany
    N Engl J Med 359:1442-55. 2008
    ....
  24. ncbi request reprint Gender differences in AIDS-associated Kaposi sarcoma in Harare, Zimbabwe
    Amie L Meditz
    Division of Infectious Diseases, Department of Medicine, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Denver, CO 80262, USA
    J Acquir Immune Defic Syndr 44:306-8. 2007
    ..7, 95% confidence interval: 1.1 to 2.7; P = 0.009). These findings suggest an increased severity of KS or other unidentified infections among women with AIDS-KS in Zimbabwe...

Research Grants9

  1. INHIBITION OF HHV 8 GENE EXPRESSION BY RIBOZYMES
    Thomas Campbell; Fiscal Year: 2001
    ....
  2. Significance of Oral KS in an African Setting
    Thomas Campbell; Fiscal Year: 2006
    ..It is expected that the results of these studies will provide useful information to programs for introduction of contemporary antiretroviral treatment in resource-limited areas of Africa. ..
  3. COLORADO AIDS CLINICAL TRIALS UNIT
    Thomas Campbell; Fiscal Year: 2007
    ..administrative component: ..
  4. Colorado HIV Research Training Program
    Thomas Campbell; Fiscal Year: 2007
    ..The success of the program will be evaluated on the basis of the extent to which it facilitates the career development of individuals who bed come productive member of the AIDS research community. ..